Financings Of The Fortnight: Idenix To Forge Ahead On HCV Combo After Novartis’ Departure
This article was originally published in The Pink Sheet Daily
Plus news on recent financial activity by Mersana Therapeutics, Hyperion Therapeutics, Atterocor and Exelixis.
You may also be interested in...
Bristol-Myers Squibb has halted study of its Phase II nucleoside polymerase inhibitor for hepatitis C due to one trial patient suffering heart failure. It remains unclear if that event is related to the study drug, but do repeated toxicity issues with “nucs” indicate a class effect?
Nine $1bn+ alliances were penned in October. Topping the list was a potential $22bn deal between Daiichi Sankyo and Merck for the global development and commercialization of Daiichi’s DXd antibody drug conjugate candidates patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan.
Due to the unprecedented growth in the development of cell and gene therapies over the past decade, there is now high demand for certain workforce roles, especially in highly specialized areas and entry-level manufacturing positions.